{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T17:56:34Z","timestamp":1781632594023,"version":"3.54.5"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T00:00:00Z","timestamp":1769731200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T00:00:00Z","timestamp":1771891200000},"content-version":"vor","delay-in-days":25,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"We appreciate the financial support from Iran University of Medical Sciences, Tehran, Iran for this study","award":["(Grant number: 26058)"],"award-info":[{"award-number":["(Grant number: 26058)"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Women's Health"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and aim<\/jats:title>\n                    <jats:p>Cervical cancer, primarily caused by Human Papillomavirus, remains a significant global health concern. Despite vaccine availability, uptake rates are low in many conservative settings, including Iran, where context-specific factors influencing vaccination are often overlooked. This qualitative study aimed to explore and articulate the perceptions, experiences, and actionable recommendations of health and social experts concerning the barriers, facilitators, and the perceived family implications of Human Papillomavirus vaccination in Iran.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This qualitative inquiry employed Conventional Content Analysis. Using Maximum Variation Purposive Sampling, 18 female experts and professionals (Obstetricians\/Gynecologists, health educators, laboratory staff, and academic researchers) were recruited from major medical universities in Tehran (January 2025 to September 2025). Data were gathered through five Focus Group Discussions (FGDs) and seven semi-structured In-depth Individual Interviews. Methodological rigor was ensured via techniques like Member Checking. Data were analyzed using MAXQDA 2020 software.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Participants included 18 female experts (mean age 44\u2009\u00b1\u200910.7 years). Thematic analysis identified 13 sub-themes categorized into five domains: (1) family awareness and information sources; (2) family attitudes and beliefs; (3) family decision-making; (4) systemic and economic barriers; and (5) family wellbeing and policy. A central finding was the synergistic interplay between high economic costs and deep-seated social stigma. This linkage perpetuates low awareness and fuels moral misconceptions (e.g., vaccine as a \u201cmoral license\u201d), which often lead to severe marital conflicts, infidelity accusations, and psychosocial distress within the family unit.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>From the Iranian experts\u2019 perspective, vaccination uptake is primarily hindered by high cost, limited access, and deeply rooted social stigma associated with sexually transmitted infections. Key actionable recommendations include full insurance coverage, introducing affordable domestic vaccines, and implementing culturally tailored public health education to address moral concerns. These findings provide crucial evidence for policymakers to design targeted interventions that improve Human Papillomavirus vaccine coverage and protect family health in Iran.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12905-026-04269-6","type":"journal-article","created":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T09:53:48Z","timestamp":1769766828000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["HPV vaccination in Iran: expert perspectives on family dynamics and barriers"],"prefix":"10.1186","volume":"26","author":[{"given":"Monireh","family":"Faghir-Ganji","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pouria","family":"Feizabadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alireza","family":"Ansari-Moghaddam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narjes","family":"Abdolmohammadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Babak","family":"Eshrati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,30]]},"reference":[{"issue":"3","key":"4269_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363.","journal-title":"CA Cancer J Clin"},{"key":"4269_CR2","unstructured":"on the Evaluation IWG. Cervical cancer. Cervical cancer screening. International Agency for Research on Cancer; 2022."},{"issue":"4","key":"4269_CR3","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1038\/nrc.2018.13","volume":"18","author":"R Roden","year":"2018","unstructured":"Roden R, Stern PL. Opportunities and challenges for human papillomavirus vaccination in cancer. Nat Rev Cancer. 2018;18(4):240\u201354.","journal-title":"Nat Rev Cancer"},{"issue":"4","key":"4269_CR4","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines11040850","volume":"11","author":"A Cernasev","year":"2023","unstructured":"Cernasev A, Hohmeier KC, Oyedeji O, Hagemann T, Kintziger KW, Wisdom T, et al. Perspectives associated with human papillomavirus vaccination in adults: a qualitative study. Vaccines. 2023;11(4):850.","journal-title":"Vaccines"},{"issue":"67","key":"4269_CR5","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1093\/jncimonographs\/lgae026","volume":"2024","author":"AE Schuind","year":"2024","unstructured":"Schuind AE, Balaji KA, Du A, Yuan Y, Dull P. Human papillomavirus prophylactic vaccines: update on new vaccine development and implications for single-dose policy. JNCI Monogr. 2024;2024(67):410\u20136.","journal-title":"JNCI Monogr"},{"issue":"8","key":"4269_CR6","doi-asserted-by":"publisher","first-page":"e2121893","DOI":"10.1001\/jamanetworkopen.2021.21893","volume":"4","author":"NF Schlecht","year":"2021","unstructured":"Schlecht NF, Diaz A, Nucci-Sack A, Shyhalla K, Shankar V, Guillot M, et al. Incidence and types of human papillomavirus infections in adolescent girls and young women immunized with the human papillomavirus vaccine. JAMA Netw Open. 2021;4(8):e2121893\u2013e.","journal-title":"JAMA Netw Open"},{"key":"4269_CR7","doi-asserted-by":"publisher","DOI":"10.1136\/bmjmed-2023-000726","author":"RM Casey","year":"2024","unstructured":"Casey RM, Akaba H, Hyde TB, Bloem P. COVID-19 pandemic and equity of global human papillomavirus vaccination: descriptive study of World Health Organization-Unicef vaccination coverage estimates. BMJ Med. 2024. https:\/\/doi.org\/10.1136\/bmjmed-2023-000726.","journal-title":"BMJ Med"},{"issue":"2","key":"4269_CR8","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/j.vaccine.2022.11.032","volume":"41","author":"A Hsiao","year":"2023","unstructured":"Hsiao A, Struckmann V, Stephani V, Mmbando D, Changalucha J, Baisley K, et al. Costs of delivering human papillomavirus vaccination using a one-or two-dose strategy in Tanzania. Vaccine. 2023;41(2):372\u20139.","journal-title":"Vaccine"},{"key":"4269_CR9","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1150238","volume":"14","author":"N Ebrahimi","year":"2023","unstructured":"Ebrahimi N, Yousefi Z, Khosravi G, Malayeri FE, Golabi M, Askarzadeh M, et al. Human papillomavirus vaccination in low-and middle-income countries: progression, barriers, and future prospective. Front Immunol. 2023;14:1150238.","journal-title":"Front Immunol"},{"issue":"20","key":"4269_CR10","doi-asserted-by":"publisher","first-page":"2975","DOI":"10.1200\/JCO.2007.10.8662","volume":"25","author":"JK Chan","year":"2007","unstructured":"Chan JK, Berek JS. Impact of the human papilloma vaccine on cervical cancer. J Clin Oncol. 2007;25(20):2975\u201382.","journal-title":"J Clin Oncol"},{"key":"4269_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102878","author":"Z Zou","year":"2024","unstructured":"Zou Z, Fairley CK, Ong JJ, Shen M, Chow EP, Liu H, et al. Impact of achieving WHO\u2019s 90-70-90 targets on cervical cancer elimination and potential benefits in preventing other HPV-related cancers in China: a modelling study. eClinMed. 2024. https:\/\/doi.org\/10.1016\/j.eclinm.2024.102878.","journal-title":"eClinMed"},{"issue":"3","key":"4269_CR12","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/S1470-2045(18)30836-2","volume":"20","author":"KT Simms","year":"2019","unstructured":"Simms KT, Steinberg J, Caruana M, Smith MA, Lew J-B, Soerjomataram I, et al. Impact of scaled up human papillomavirus vaccination and cervical screening and the potential for global elimination of cervical cancer in 181 countries, 2020\u201399: a modelling study. Lancet Oncol. 2019;20(3):394\u2013407.","journal-title":"Lancet Oncol"},{"issue":"1","key":"4269_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4103\/ijpvm.IJPVM_599_20","volume":"13","author":"S Yarmohammadi","year":"2022","unstructured":"Yarmohammadi S, Ghaffari M, Mashayekhi P, Ramezankhani A, Mirzaei J. Strategies for improving participation in human papillomavirus vaccination among young adults in the capital of Iran: a qualitative\u2013exploratory study. Int J Prev Med. 2022;13(1):1.","journal-title":"Int J Prev Med"},{"issue":"4","key":"4269_CR14","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.vacun.2023.06.002","volume":"24","author":"M Honarvar","year":"2023","unstructured":"Honarvar M, Goudarzi R, Amiresmaili M, Amiri A, Paul ASS. The feasibility of including human papillomavirus vaccine in Iran\u2019s national immunization program. Vacunas. 2023;24(4):298\u2013307.","journal-title":"Vacunas"},{"key":"4269_CR15","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.vhri.2018.03.001","volume":"15","author":"M Yaghoubi","year":"2018","unstructured":"Yaghoubi M, Nojomi M, Vaezi A, Erfani V, Mahmoudi S, Ezoji K, et al. Cost-effectiveness analysis of the introduction of HPV vaccination of 9-year-old-girls in Iran. Value in health regional issues. 2018;15:112\u20139.","journal-title":"Value in health regional issues"},{"issue":"1","key":"4269_CR16","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1111\/j.1365-2648.2007.04569.x","volume":"62","author":"S Elo","year":"2008","unstructured":"Elo S, Kyngas H. The qualitative content analysis process. J Adv Nurs. 2008;62(1):107\u201315.","journal-title":"J Adv Nurs"},{"issue":"9","key":"4269_CR17","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1177\/1049732305276687","volume":"15","author":"HF Hsieh","year":"2005","unstructured":"Hsieh HF, Shannon SE. Three approaches to qualitative content analysis. Qual Health Res. 2005;15(9):1277\u201388.","journal-title":"Qual Health Res"},{"issue":"1","key":"4269_CR18","doi-asserted-by":"publisher","first-page":"48","DOI":"10.4274\/jtgga.galenos.2022.2022-6-6","volume":"24","author":"S Hakimi","year":"2023","unstructured":"Hakimi S, Lami F, Allahqoli L, Alkatout I. Barriers to the HPV vaccination program in the Eastern Mediterranean region: a narrative review. J Turkish German Gynecol Association. 2023;24(1):48.","journal-title":"J Turkish German Gynecol Association"},{"issue":"3","key":"4269_CR19","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1213\/ANE.0000000000005858","volume":"134","author":"A Abd-Elsayed","year":"2022","unstructured":"Abd-Elsayed A, D\u2019Souza RS. The burden of coronavirus disease 2019\u2013related cases, hospitalizations, and mortality based on vaccination status and mandated mask use: statewide data from Wisconsin and narrative review of the literature. Anesth Analg. 2022;134(3):524\u201331.","journal-title":"Anesth Analg"},{"issue":"5","key":"4269_CR20","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines13050460","volume":"13","author":"G Cangelosi","year":"2025","unstructured":"Cangelosi G, Sacchini F, Mancin S, Petrelli F, Amendola A, Fappani C, et al. Papillomavirus vaccination programs and knowledge gaps as barriers to implementation: a systematic review. Vaccines. 2025;13(5):460.","journal-title":"Vaccines"},{"issue":"6","key":"4269_CR21","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1007\/s10935-022-00697-w","volume":"43","author":"N Sargazi","year":"2022","unstructured":"Sargazi N, Takian A, Daroudi R, Nahvijou A, Yaseri M, Ghanbari Motlagh A, et al. Cost\u2013benefit analysis of human papillomavirus vaccine in Iran. J Prev. 2022;43(6):841\u201357.","journal-title":"J Prev"},{"issue":"5","key":"4269_CR22","doi-asserted-by":"publisher","first-page":"343","DOI":"10.34172\/aim.2022.56","volume":"25","author":"M Fakhrolmobasheri","year":"2022","unstructured":"Fakhrolmobasheri M, Seresht LM. Cost-effectiveness of HPV vaccination; need for economic and social policy intervention. Arch Iran Med. 2022;25(5):343.","journal-title":"Arch Iran Med"},{"key":"4269_CR23","doi-asserted-by":"publisher","DOI":"10.34172\/ijhpm.9020","author":"S Babaeifard","year":"2025","unstructured":"Babaeifard S, Barkhordar M, Aliabadi LS, Marzban M, Rouzbahani H, Razani G, et al. Comprehensive national strategy for HPV prevention and treatment in Iran. Int J Health Policy Manag. 2025. https:\/\/doi.org\/10.34172\/ijhpm.9020.","journal-title":"Int J Health Policy Manag"},{"key":"4269_CR24","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-025-25583-y","author":"L Alizadeh","year":"2025","unstructured":"Alizadeh L, Keshavarz Z, Shalbaf A, Iranpour S. Iranian women\u2019s perceptions of human papillomavirus and barriers to vaccination: a qualitative study based on the health belief model. BMC Public Health. 2025. https:\/\/doi.org\/10.1186\/s12889-025-25583-y.","journal-title":"BMC Public Health"},{"key":"4269_CR25","first-page":"256","volume-title":"Stigma and social identity","author":"E Goffman","year":"2014","unstructured":"Goffman E. Stigma and social identity. Understanding deviance: Routledge; 2014. pp. 256\u201365."},{"key":"4269_CR26","unstructured":"Goffman E. Stigma and social identity. The Body-Critical Concepts in Sociology. 2004:116\u2009\u2013\u200944."},{"issue":"2","key":"4269_CR27","first-page":"116","volume":"14","author":"N Soltanizadeh","year":"2020","unstructured":"Soltanizadeh N, Shahrabi MA, Masjedi MR, Ainy E, Kavousy E, Hashemi SM. Health culture and presenting a paradigmatic model focusing on human papillomavirus disease. J Fam Reprod Health. 2020;14(2):116.","journal-title":"J Fam Reprod Health"},{"issue":"1","key":"4269_CR28","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/s12905-021-01272-x","volume":"21","author":"K Qaderi","year":"2021","unstructured":"Qaderi K, Mirmolaei ST, Geranmayeh M, Sheikh Hasani S, Farnam F. Iranian women\u2019s psychological responses to positive HPV test result: a qualitative study. BMC Womens Health. 2021;21(1):128.","journal-title":"BMC Womens Health"},{"issue":"7","key":"4269_CR29","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1080\/21645515.2020.1756670","volume":"16","author":"LP Wong","year":"2020","unstructured":"Wong LP, Wong P-F, Megat Hashim MMAA, Han L, Lin Y, Hu Z, et al. Multidimensional social and cultural norms influencing HPV vaccine hesitancy in Asia. Hum Vaccines Immunotherapeutics. 2020;16(7):1611\u201322.","journal-title":"Hum Vaccines Immunotherapeutics"},{"issue":"2","key":"4269_CR30","first-page":"92","volume":"9","author":"N Nick","year":"2021","unstructured":"Nick N, Torabizadeh C, Ghahartars M. Perceived supportive paradox after diagnosing human papillomavirus: a qualitative content analysis. Int J Community Based Nurs Midwifery. 2021;9(2):92.","journal-title":"Int J Community Based Nurs Midwifery"},{"key":"4269_CR31","doi-asserted-by":"publisher","DOI":"10.1177\/00469580221150094","volume":"60","author":"M Galeshi","year":"2023","unstructured":"Galeshi M, Shirafkan H, Yazdani S, Motaghi Z. Challenges and needs of HPV-positive women. Inquiry. 2023;60:00469580221150094.","journal-title":"Inquiry"}],"container-title":["BMC Women's Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12905-026-04269-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12905-026-04269-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12905-026-04269-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T17:23:53Z","timestamp":1781630633000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12905-026-04269-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,30]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4269"],"URL":"https:\/\/doi.org\/10.1186\/s12905-026-04269-6","relation":{},"ISSN":["1472-6874"],"issn-type":[{"value":"1472-6874","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,30]]},"assertion":[{"value":"16 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Committee of Iran University of Medical Sciences (Ethics Code: IR.IUMS.REC.1402.869). The study was conducted in accordance with the Declaration of Helsinki. Written informed consent was obtained from all participants before their inclusion in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"135"}}